
Obstructive sleep apnoea (OSA), characterized by recurrent periods of upper airway obstruction and intermittent hypoxaemia, is prevalent in patients with cardiovascular disease (CVD) and is, therefore, essential to consider in the prevention and management of CVD. Furthermore, novel sleep apnoea-associated hypoxic burden markers and cardiac autonomic response have emerged as predictors of OSA-related susceptibility to adverse health outcomes and treatment response. This review summarizes the understanding of the shared risk factors and causal links between OSA and CVD and emerging knowledge on the heterogeneity of OSA. In addition, it discusses the varied mechanistic pathways that result in CVD that also vary across subgroups of OSA, as well as the potential role of new biomarkers for CVD risk stratification.
Like
Save
Share